Rapid Lateral Flow Assay Detects Several Viral Fevers Simultaneously
|
By LabMedica International staff writers Posted on 10 Mar 2015 |

Image: The diagnostic system is based on triangular silver nanoparticles that display different colors depending on their size (Photo courtesy of the Massachusetts Institute of Technology).
A team of biomedical engineers has developed a rapid diagnostic test that is able to detect several viruses such as Ebola, dengue fever, and yellow fever simultaneously from a single sample of patient's serum.
Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Harvard Medical School (Boston, MA, USA) used a novel class of silver nanoparticles to drive a paper-based lateral flow assay. Lateral flow assays are commonly used to detect such pathogens as Rotavirus, adenovirus, Streptococcus A and B, and gonorrhea and in rapid pregnancy tests.
The investigators extended the usefulness of the lateral flow approach by incorporating antibodies bound to different colored nanoparticles. In the current version of the assay, following a 10 minute incubation, an orange band indicates the presence of yellow fever virus, a red band indicates Ebolavirus, and a green band indicates dengue fever virus.
The investigators expect that their new rapid test will complement more definitive diagnostic technologies, such as PCR. "If you are in a situation in the field with no power and no special technologies, if you want to know if a patient has Ebola, this test can tell you very quickly that you might not want to put that patient in a waiting room with other people who might not be infected," said senior author Dr. Lee Gehrke, professor of microbiology and immunology at Harvard Medical School. "That initial triage can be very important from a public health standpoint, and there could be a follow-up test later with PCR or something to confirm."
This type of diagnostic testing device is readily customizable to detect other infectious diseases, by linking the silver nanoparticles to different antibodies. "Thankfully the Ebola outbreak is dying off, which is a good thing, but what we are thinking about is what is coming next," said Dr. Gehrke. "There will undoubtedly be other viral outbreaks. It might be Sudan virus, or it might be another hemorrhagic fever. What we are trying to do is develop the antibodies needed to be ready for the next outbreak that is going to happen."
The rapid diagnostic test for multiple viral fevers was described in the February 12, 2015, online edition of the journal Lab on a Chip.
Related Links:
Massachusetts Institute of Technology
Harvard Medical School
Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Harvard Medical School (Boston, MA, USA) used a novel class of silver nanoparticles to drive a paper-based lateral flow assay. Lateral flow assays are commonly used to detect such pathogens as Rotavirus, adenovirus, Streptococcus A and B, and gonorrhea and in rapid pregnancy tests.
The investigators extended the usefulness of the lateral flow approach by incorporating antibodies bound to different colored nanoparticles. In the current version of the assay, following a 10 minute incubation, an orange band indicates the presence of yellow fever virus, a red band indicates Ebolavirus, and a green band indicates dengue fever virus.
The investigators expect that their new rapid test will complement more definitive diagnostic technologies, such as PCR. "If you are in a situation in the field with no power and no special technologies, if you want to know if a patient has Ebola, this test can tell you very quickly that you might not want to put that patient in a waiting room with other people who might not be infected," said senior author Dr. Lee Gehrke, professor of microbiology and immunology at Harvard Medical School. "That initial triage can be very important from a public health standpoint, and there could be a follow-up test later with PCR or something to confirm."
This type of diagnostic testing device is readily customizable to detect other infectious diseases, by linking the silver nanoparticles to different antibodies. "Thankfully the Ebola outbreak is dying off, which is a good thing, but what we are thinking about is what is coming next," said Dr. Gehrke. "There will undoubtedly be other viral outbreaks. It might be Sudan virus, or it might be another hemorrhagic fever. What we are trying to do is develop the antibodies needed to be ready for the next outbreak that is going to happen."
The rapid diagnostic test for multiple viral fevers was described in the February 12, 2015, online edition of the journal Lab on a Chip.
Related Links:
Massachusetts Institute of Technology
Harvard Medical School
Latest Microbiology News
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more








